EHA23 – Novel CAR Therapy for AML Shows Favorable Pre-Clinical Outcomes
A novel combinatorial CAR therapy ADCLEC.syn1, designed to co-target ADGRE2 and CLEC12A for selective elimination of AML, shows exciting results.
A novel combinatorial CAR therapy ADCLEC.syn1, designed to co-target ADGRE2 and CLEC12A for selective elimination of AML, shows exciting results.